YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates. The biopharmaceutical company, which focuses on treatments for brain disorders, used the…
Ovid Therapeutics Inc. NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today…
Ovid Therapeutics (OVID) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earning…
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business…
(RTTNews) - Wedbush analysts on Tuesday reiterated Ovid Therapeutics (OVID) at Outperform rating with a price target of $7. Analyst Laura Chico noted that the upcoming KCC2 R&D Event, scheduled for April 14, 2026, is an important catalyst…
Ovid Therapeutics(NASDAQ: OVID) stock rose by more than 18% as of 12 a.m. today. The biopharmaceutical company is devoted to developing medicines for people with epilepsy and other brain conditions, and today's rise follows some positive n…
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures and an open-label, pr…
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items. Th…
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best fast growing penny stocks to buy according to analysts. Earlier on December 22, LifeSci Capital initiated coverage of Ovid Therapeutics with an Outperform rating and set a price targe…
As the U.S. stock market continues to reach new heights, with major indices like the Dow Jones and S&P 500 setting all-time records, investors are exploring diverse opportunities across various sectors. Penny stocks, often overlooked yet i…
(RTTNews) - Ovid Therapeutics Inc. (OVID) on Tuesday announced the appointment of Petra Kaufmann as its chief medical officer. Kaufmann brings extensive experience from both the biopharmaceutical industry and the U.S. National Institutes o…
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Ka…
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items. Th…
* Ovid Therapeutics press release [https://seekingalpha.com/pr/20303367-ovid-therapeutics-announces-planned-leadership-succession-and-reports-business-updates-and] (OVID [https://seekingalpha.com/symbol/OVID]): Q3 GAAP EPS of -$0.17 misses…
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong…
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer Physician-scientist brings more than two decades of R&D leadership experience in neuroscience, rare disease, and pain modulation at organizations including Abb…
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This…
Wall Street expects a year-over-year increase in earnings on higher revenues when Ovid Therapeutics (OVID) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company'…
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the hot stocks to buy with huge upside potential. On October 10, B. Riley raised the firm’s price target on Ovid Therapeutics to $5 from $3 and kept a Buy rating on the shares. This price targ…
Shares of Ovid Therapeutics OVID rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage study of the company’s lead investigational candidate, OV329. The candidate is a next-generation GABA-AT inhibitor…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk/iStock via Getty Images Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) added ~13% on Thursday after Wedbush revised its rating to Outperform from not rated, cit…
[Doctor writing word Epilepsy with marker, Medical concept] Michail_Petrov-96/iStock via Getty Images * Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) stock rose after encouraging results from its early stage study…
Health care stocks were advancing premarket Friday, with the Health Care Select Sector SPDR Fund (XL PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) entered into a securities purchase agreement [https://seekingalpha.com/pr/20253919-ovid-therapeutics-announces-pricing-of-private-placement-totaling-up-to-175-million…
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has e…
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metrics OV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT i…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close mov…
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ST…
Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a price target of $5.50, reflecting a pote…
As the U.S. market navigates a period of volatility marked by tech stock declines and fluctuating indices, investors are keenly watching for opportunities that might offer stability amidst uncertainty. Penny stocks, though an older term, s…
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT WBTN [https://www.chartmill.com/st…
* Ovid Therapeutics press release [https://seekingalpha.com/pr/20199310-ovid-therapeutics-reports-business-updates-and-second-quarter-2025-financial-results] (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]): Q2 GAAP EPS of -$0.06. * Re…
Investing.com - Lucid Capital Markets initiated coverage on Ovid Therapeutics Inc (NASDAQ:OVID) with a Buy rating and a $5.50 price target on Wednesday. The target represents significant upside potential for the $38.9 million market cap co…
Investing.com - B.Riley has assumed coverage on Ovid Therapeutics Inc (NASDAQ:OVID) with a Buy rating and a $3.00 price target, according to a research note released Friday. According to InvestingPro data, the stock appears undervalued bas…
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics announced a definitive agreement with Immedica Pharma AB. Under this agreement, Ovid will sell its future royalty right…